Menu

Alzheimer’s Should be Characterized by Biomarkers: Report

A proposed definition of the disease emphasizes signs of neurodegeneration and the presence of β-amyloid and tau, rather than cognitive symptoms.

Apr 10, 2018
Diana Kwon

Neurofibrillary tangles in the hippocampus of a patient with Alzheimer-related pathology.WIKIMEDIA, PATHO

Alzheimer’s disease should be defined by changes in the brain rather than cognitive symptoms such as memory decline, according to a report published today (April 10) in Alzheimer’s & Dementia

This proposal, which was put forth by the Alzheimer’s Association and the National Institute on Aging, suggests that Alzheimer’s patients should be defined by in vivo biomarkers, such as brain scans to identify neurodegeneration or spinal fluid tests to detect β-amyloid and tau, two proteins involved in the pathology of the disease.

“What we’re seeing now is that Alzheimer’s disease is defined by the presence of plaques and tangles in your brain,” Clifford Jack, a Mayo Clinic brain imaging specialist and coauthor of the report, tells NPR. Within this framework, he adds, “symptoms become the result of the disease, not the definition of the disease.”

Through this new definition, the number of people considered to have Alzheimer’s “will increase dramatically,” Jack tells the Associated Press. “There are a lot more cognitively normal people who have the pathology in the brain who will now be counted as having Alzheimer’s disease.”

The authors of the report note that this definition is meant to be used in observational and interventional research, not the clinic. “It’s a research framework meant to be tested, a tool for researchers, not for the doctor’s office,” coauthor Maria Carrillo, chief scientific officer of the Alzheimer's Association, tells NPR. She adds that biomarker-based tests could one day help prevent the disease, once effective drugs are available.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.